Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$199.02
-3.5%		$227.43
$112.90
▼
$260.19
$10.42B0.65677,812 shs441,177 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$84.84
0.0%		$73.98
$30.25
▼
$84.89
$9.00B0.122.24 million shs1.13 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.17
+0.1%		$12.86
$11.36
▼
$15.67
$10.17B0.292.36 million shs1.67 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%-4.21%-15.18%-15.12%+63.32%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
0.00%+0.18%+1.45%+138.65%+179.08%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.00%-0.16%+2.66%-10.81%-14.51%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$199.02
-3.5%		$227.43
$112.90
▼
$260.19
$10.42B0.65677,812 shs441,177 shs
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$84.84
0.0%		$73.98
$30.25
▼
$84.89
$9.00B0.122.24 million shs1.13 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
▼
$19.50
$2.86B1.21.02 million shsN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$12.17
+0.1%		$12.86
$11.36
▼
$15.67
$10.17B0.292.36 million shs1.67 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%-4.21%-15.18%-15.12%+63.32%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
0.00%+0.18%+1.45%+138.65%+179.08%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.00%-0.16%+2.66%-10.81%-14.51%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.91
Moderate Buy$267.6034.46% Upside
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.24
Hold$81.00-4.53% Downside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest MOR, AXSM, RDY, and CRNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/24/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/18/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/12/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$306.00 ➝ $316.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$304.00 ➝ $297.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$242.00 ➝ $251.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$260.00 ➝ $275.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy ➝ Market Perform
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$255.00 ➝ $256.00
8/11/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$267.00 ➝ $268.00
7/28/2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$55.00 ➝ $85.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$776.57M13.42N/AN/A$1.59 per share125.17
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$42.16M213.46N/AN/A$11.24 per share7.55
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$331.19B0.03$0.85 per share14.38$4.90 per share2.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.75N/A49.02N/A-24.68%-265.55%-28.10%11/2/2026 (Estimated)
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$465.32M-$5.04N/AN/AN/A-1,189.88%-44.22%-39.77%11/5/2026 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$456M$0.4427.6621.352.5510.15%9.49%6.32%10/23/2026 (Estimated)

Latest MOR, AXSM, RDY, and CRNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.8921-$0.99-$0.0980-$0.99$221.11 million$218.38 million
8/3/2026Q2 2026
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$1.18-$1.14+$0.04-$1.14$14.84 million$25.12 million
7/23/2026Q1 26/27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.0918$0.06-$0.0318$0.06$850.56 million$850.26 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.060.49%+6.96%13.64%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.52
1.43
1.34
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
15.57
15.53
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.90
1.39

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.80%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38052.38 million41.59 millionOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
210106.07 million102.04 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,527834.67 million817.97 millionOptionable

Recent News About These Companies

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to Hold at Wall Street Zen
August 29 at 1:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-dr-reddys-laboratories-nyse-rdy-upgraded-to-hold-at-wall-street-zen-2026-08-29/
Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Bank of America Corp DE
August 28 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dr-reddys-laboratories-ltd-rdy-shares-sold-by-bank-of-america-corp-de-2026-08-28/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
August 27 at 4:15 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddys-laboratories-limited---rdy-302862236.html
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350986/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dr-reddy-s-laboratories-limited-rdy.html
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/08/19/10432956.htm
Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
August 19, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260819170238/en/securities-fraud-investigation-into-dr.-reddy%e2%80%99s-laboratories-rdy-announced-%e2%80%93-shareholders-who-lost-money-urged-to-contact-the-law-offices-of-frank-r.-cruz/
RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
August 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260813865879/en/rdy-shareholder-alert-dr.-reddy%e2%80%99s-laboratories-investors-encouraged-to-contact-kirby-mcinerney-llp-about-potential-securities-laws-violations/
Dr. Reddy's Laboratories Ltd. Sponsored ADR
August 12, 2026  |  cnn.comhttps://www.cnn.com/markets/stocks/RDY
Zacks Research Issues Optimistic Forecast for RDY Earnings
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zacks-research-issues-optimistic-forecast-for-rdy-earnings-2026-08-12/
Zacks Research Issues Pessimistic Outlook for RDY Earnings
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/zacks-research-issues-pessimistic-outlook-for-rdy-earnings-2026-08-11/
Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy's Laboratories Ltd $RDY
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-buys-shares-of-102643-dr-reddys-laboratories-ltd-rdy-2026-08-06/
Dr. Reddy's Laboratories Launches Sugammadex Injection Single-Dose Vials in US
August 5, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dr-reddy-apos-laboratories-launches-092633479.html
DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3339873/937/en/dr-reddy-s-laboratories-investor-alert-kirby-mcinerney-llp-announces-investigation-into-potential-securities-fraud.html
Dr. Reddy's Laboratories Ltd $RDY Shares Purchased by Quantinno Capital Management LP
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dr-reddys-laboratories-ltd-rdy-shares-purchased-by-quantinno-capital-management-lp-2026-08-05/
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of ...
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/dr-reddy-announces-first-market-053900460.html
Sei Investments Co. Increases Stock Position in Dr. Reddy's Laboratories Ltd $RDY
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-increases-stock-position-in-dr-reddys-laboratories-ltd-rdy-2026-08-04/
Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
August 4, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260729613216/en/Dr.-Reddy%E2%80%99s-Announces-the-First-to-Market-Launch-of-Sugammadex-Injection-200-mg2-mL-100-mgmL-and-500-mg5-mL-100-mgmL-Single-Dose-Vials-a-Generic-Equivalent-of-Bridion%C2%AE-in-the-United-States/
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
July 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/dr-reddys-laboratories-rdy-securities-investigation-notice---levi--korsinsky-302839636.html
Royal Bank of Canada Buys 434,805 Shares of Dr. Reddy's Laboratories Ltd $RDY
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-buys-434805-shares-of-dr-reddys-laboratories-ltd-rdy-2026-07-31/
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335383/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-dr-reddy-s-laboratories-rdy.html
Dr Reddys Laboratories Ltd (RDY)
July 28, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/insider-trading/company/dr+reddys+laboratories+ltd/1135951/news/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Trading floor with digital stock displays and workstations, overlaid with the text "S&P 500".
5 Reasons the S&P 500 Could Keep Rallying Through Year-End
By Thomas Hughes | August 20, 2026
Williams Sonoma circular logo sign on a wall surrounded by kitchenware, bowls, a pepper mill, and cutting board.
Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
By Thomas Hughes | August 26, 2026
Red SanDisk external SSD on a gray surface beneath a glowing red SanDisk logo, clean product-style lighting.
Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is Falling
By Sam Quirke | August 6, 2026
Large outdoor display shows a declining red stock price chart amid downtown office towers with pedestrians walking nearby.
Asian Market Circuit Breakers Hit Stocks, Not AI Demand
By Jeffrey Neal Johnson | August 13, 2026
Pink Apple iPhone 18 with triple-camera system shown from the back against a pink illuminated background.
Apple’s Next iPhone Could Test How Much Pricing Power Is Left
By Sam Quirke | August 11, 2026
Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$199.02 -7.25 (-3.51%)
As of 08/28/2026 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.84 -0.01 (-0.01%)
As of 08/28/2026 04:00 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 08/28/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$12.17 +0.01 (+0.08%)
As of 08/28/2026 03:58 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas